Headquartered in Malvern, Pennsylvania, Encore Dermatology was a privately held dermatology company delivering prescription therapies and medical devices to dermatologists.
Encore was led by the CEO and management team of one of EW’s prior growth equity deals, PreCision Dermatology. The Encore assets were medical dermatology products, including Impoyz, Sernivo, Trianex, Okebo and Promiseb. Impoyz was indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age and older, Sernivo Spray was for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older, Trianex ointment was for the treament of widespread eczema, Okebo capsules were a tetracycline-class antibacterial and could be used as adjunctive therapy in severe acne, and Promiseb topical cream was a nonsteroidal prescription cream indicated to manage and relieve the signs and symptoms of seborrheic dermatitis.
“I have been on the Board of Directors of three EW-backed companies: as Chairman, as Executive Chairman, and as the only US-based Director. EW played a key role in building these three rapidly growing companies. The EW team are true partners with the management teams they back. I look forward to the fourth deal!”
William W. Crouse
Executive Chairman, Encore Dermatology
Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.